NCT06646783

Phase IIT Trial of SNA014

Clinical Study of 68GA-labeled Claudin 18.2 Developer Combined with PET/CT for Imaging of Gastric or Gastroesophageal Junction Adenocarcinoma and Pancreatic Cancer

• Status: Not Yet Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 28 (estimated)
• Sponsor: SmartNuclide Biopharma · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

68Ga labeled Claudin 18.2 contrast agent combined with PET/CT for gastric or gastroesophageal junction

Conditions

• Adenocarcinoma of the Stomach
• Adenocarcinoma of GE Junction
• Pancreatic Cancer Stage

Interventions

Type	Name	Description
DRUG	[68Ga]Ga-NODAGA-SNA014	Perform whole-body PET/CT scans on the subjects at 30 minutes (± 5 minutes), 60 minutes (± 10 minutes), 120 minutes (± 20 minutes), and 240 minutes (± 30 minutes) after administration. Among them, PET scanning can be performed on 1-2 subjects in a certain dose group or each dose group for 30-60 minutes. Among the four CT scans, one CT scan is a conventional low-dose CT scan (120mA), and the remaining three are extremely low-dose CT scans (10-20mA). The main researchers and nuclear medicine physicians can decide whether to change the subsequent image acquisition time and duration of the subjects based on the image information obtained from the enrolled subjects.

Timeline

• Start date: 2024-10-20
• Primary completion: 2025-10-20
• Completion: 2025-11-20
• First posted: 2024-10-17
• Last updated: 2024-10-17

Locations

1 site across 1 country: China